Business Context and Reporting Period
Company: Supernus Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 10, 2012
Reporting Period: Three and six months ended June 30, 2012
This filing serves as a notification that the Company issued a press release detailing its financial results for the periods mentioned above. The actual financial data is contained within the press release furnished as Exhibit 99.1 and incorporated by reference.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release (Exhibit 99.1) but are not present in the body of this Form 8-K.
Material Changes
The filing text does not provide specific details regarding material changes versus prior comparable periods. It only confirms the issuance of results for the three and six months ending June 30, 2012.
Guidance, Outlook, and Risks
The filing text does not include management commentary, forward-looking guidance, specific risk factors, or contingencies. It strictly references the existence of a press release containing the financial performance data.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 10, 2012) for specific revenue, net loss, and cash position figures.
- Verify the Company's cash runway and burn rate as reported in the referenced press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the full press release.
- Confirm if the financial results met or missed any previously issued guidance.